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gamma knife, one fractionated stereotactic radiotherapy (SRT) by 
linac, and 9 conventionally-fractionated 3-dimensional conformal 
radiotherapies (3DCRTs). All but one patient had gross residual or 
recurrent tumor at the time of radiotherapy. Median doses were 18 Gy 
(range: 12-20 Gy) at tumor margin for SRS, and 60 Gy (range: 54-60 
Gy) for 3DCRT. SRT dose was 36 Gyin 6 fractions at isocenter. 
Results: Intracranial recurrences were observed after 28 treatment 
sessions in 20 patients, and 9 patients died with a median follow-up of 
17.7 months (range: 2-65 months). Local control rates at 1 year and 2 
years were 60.9% and 22.2%, respectively. Atypical hisotologies and 
higher dose treatments (BED3> 125Gy) appeared better local control, 
but the differences were not statistically significant (p values were 
0.072 and 0.097 respectively). Among 5 patients with intracranial 
recurrences after linac radiotherapy, 4 patients had recurrences from 
high dose regions, and marginal recurrence was seen in another 
patient. Among 23 recurrent patients with gamma knife, 2, 6, and 9 
patients experienced central, marginal, and distant recurrences, and 
data on recurrence sites were not available in other 6 patients. The 
patterns of recurrence were significantly different between linac and 
gamma knife groups (p=0.006). 
Conclusions: Our data suggested that it require high dose to the gross 
tumor and prophylactic dose around the tumor for a good local control 
of atypical or anaplasitc meningioma. Treatment results might be 
improved by combined treatment strategy of 3DCRT and stereotactic 
irradiation boost for atypical and anaplasitc meningiomas. 
   
EP-1010   
Intensity-modulated radiation therapy (IMRT) for total body 
irradiation (TBI): A dosimetric comparison 
M. Yamamoto1, T. Itou1, K. Okikawa1, M. Kido1, A. Kimura1 
1Kure National Hospital Chugoku District Cancer Centre, Hematology, 
Kure Hiroshima, Japan  
  
Purpose/Objective: TBI is an important part of conditioning regimens 
in patients undergoing hematopoietic cell transplantation (HCT). IMRT 
coupled with image-guided radiation therapy produces highly 
conformal dose distributions in the target volumes and reduces the 
dose to critical organs. We will plan IMRT for TBI to quantify the 
dosimetric gains when compared to traditional techniques. 
Materials and Methods: Four patients treated at our institution were 
chosen and 4 patients’ head-to-thigh computed tomographic images 
were used in this study. We defined the target as the body volume 
without the total lung and kidneys for myeloablative regimens and the 
body volume for nonmyeloablative and reduced intensity regimens. A 
traditional 3D plan along with an IMRT plan was computed for each 
patient. The planned doses were 2Gy/1fr., 12Gy/6fr., 4Gy/2fr. and 
4Gy/2fr.. The traditional and the IMRT techniques used opposed 
lateral fields and helical tomotherapy, respectively. 
Results: Homogeneity index (HI) was 0.12 (range, 0.07-0.20) for IMRT 
plans and 0.34 (range, 0.25-0.40) for traditional 3D plans. The total 
lung and kidney average doses were 8.1Gy and 10.4Gy, respectively, 
for IMRT plan and 10.3Gy and 11.7Gy, respectively, for a traditional 
plan in myeloablative regimens. 
Conclusions: IMRT for TBI has a dosimetric advantage in both target 
coverage and critical organ sparing over traditional beam 
arrangement. 
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Purpose/Objective: To determine the efficacy of Whole Brain 
Radiotherapy (WBRT) with carboplatin as radiation sensitizer in 
metastatic brain disease in our adult population. 
Materials and Methods: Forty two patients with metastatic brain 
disease having ECOG performance status (PS) 3 or less with normal 
haematological and biochemical profile were treated with WBRT with 
6MV Photon beam on linear accelerator using parallel opposed lateral 
beams to a dose of 30 Gys in 10 fractions. Carboplatin was 
administered in a dose of 150 mg/m2 on day 1 and 6 of WBRT. 
Improvement in PS and radiological response on CT scan/MRI brain 
before and 30 days after the WBRT using RECIST criteria was 
evaluated. 
Results: Out of 42 patients, 38 (90%) showed improvement in PS, 4 
(10%) showed either no improvement or worsening of PS (p ? 0.001). 
Seventeen (41%) patients had complete response,19 (45%) had partial 
response, 3 (7%) showed stable disease and 3 (7%) had progressive 
disease. None of the patient showed grade 3/4 toxicity during 
treatment. 
Conclusions: WBRT with carboplatin as radiation sensitizer is 
effective in palliation of patients with metastatic brain disease. Large 
scale randomised controlled trials are needed before making changes 
in routine clinical practice. 
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Purpose/Objective: Head and neck patients have been treated with 
IMRT in the radiotherapy department of our hospital since 2007, after 
a complete renewal of equipment. In a first phase direct planning has 
been used followed by inverse optimization after the learning curve 
has attained stability. ICRU 83 recommendations have been smoothly 
incorporated. During this period the registration process for treatment 
outcome assessment has also been restructured with the development 
of a digital platform enabling the comprehensive registration of both 
early and late effects and tumour response parameters. An overview 
of the clinical results that were electronically recorded in this 
platform since the middle of 2011 will be presented. 
Materials and Methods: From the treated patients the response to RT 
of 268 has already been documented in the electronic RT health 
system. Tumour cases were divided as: larynx (21.3%); oropharynx 
(20.9%); oral cavity (18.3%); nasopharynx (14.6%); hypopharynx (8.6%); 
pharyngeal-laryngeal (8.6%) and other pathology (7.8%). Mean age was 
57±12.6 years and mean prescribed dose was 65.6±4.9Gy. Direct 
optimization was used in 31.6% of the clinical cases and inverse IMRT 
in 50.4%. The remaining 18% corresponded to simpler clinical cases 
where 3D-CRT with less than 10 beam incidences have been sufficient 
to reach the treatment objectives in terms of conformality. The mean 
follow-up was 8 months (ranging from 0 days to 5 years) corresponding 
to a weekly periodicity during treatment followed by 3 monthly 
spaced visits during 2 years and then every 6 months. Complications 
for salivary glands, mucous membrane, esophagus, larynx, pharynx, 
mandible, skin, pain, ear, teeth and weight loss were reported 
through the digital platform on the basis of RTOG and CTCAE v3.0 
guidelines. 
Results: For a follow-up of 24 months in patients with stage I,II 
(19.4%) and III,IV (80.6%) local regional control was 86%, was disease 
free survival was 86% and 79% and overall survival rate was 100% and 
84%, respectively. For salivary glands no complications with grade (G) 
larger than 2 were reported. Maximum incidence of G2 complications 
was 41% for the seventh week of treatment which was reduced to 
12%for a follow-up of 2 years. Mucositis was reported with G2 and G3 
mostly during treatment (46%) that prevailed 6 months after 
treatment just for 4 patients (9%). Time evolution of esophagus, 
larynx and pharynx complications showed a similar pattern with just 
residual G3 cases and with G2 maximum incidence at the end of the 
treatment.  
Conclusions: The electronic patient information system developed 
and in use clinically is a very useful tool during the medical 
appointment for fast and systematic registration of patient response 
to RT. The comprehensive nature of this database enabled easy 
statistical assessment of patient treatment outcome and has further 
potentialities for radiobiological studies. 
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Purpose/Objective: To study the effect of HDR Interstitial 
Brachytherapy boost to EBRT in early stage T1/T2 and with concurrent 
chemoradiotherapy in T1 to T3 with N1/N2a/N2b or T3N0 squamous 
cell carcinoma of buccal mucosa, anterior 2/3rdtongue and floor of 
mouth in local control in adults as very few trials and review 
literatures have been reported in this. 
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Materials and Methods: Type of study : Descriptive study 
24 Eligible patients with age less than 61 years were included in this 
study from October 2011. Informed consent was obtained. Dental 
prophylaxis was carried out in all before the treatment. The patients 
were treated after evaluation and according to the stage of the 
disease. 13/24patients (54.16%) were locally advanced and 11/24 
patients (45.83%) were early stage. All of them received treatment as 
per protocol. Early stages T1/T2 and N0 were treated with EBRT 
(bilateral opposing fields or anterolateral wedge field to face and 
neck) dose of 44 Gy followed by 6 Gy with off cord (total dose 
50Gy/25#) was given to the primary as well as the regional lymph 
nodes of upper neck. This was followed by HDR interstitial 
brachytherapy boost of 2.5Gy per fraction or 3.5Gy per fraction for 6 
fractions twice daily with 6 to 8hrs interval between two fractions. 
Low anterior neck field (for lymph nodes) received 50 Gy per 25 
fractions. Locally advanced T1-T3 with N1, N2a, N2b or T3N0 diseases 
were treated similarly as mentioned above along with concurrent 
chemotherapy Cisplatin (70 mg/m2 every 3 weeks) and 16 Gy Electron 
boost/photon boost (if nodes are involved). Under general 
anaesthesia, trocars and hollow needles were inserted as guide tubes 
in and around the tumour 1cm apart in a single or multiple planes 
through which plastic tubes were threaded. These tubes were then 
secured by buttons. On 2nd post op day patients were simulated with 
CT scan. The CT images were transferred to the treatment planning 
system. The target was delineated in the planning system and 3D 
treatment plan was made to deliver the dose to the target. The effect 
of treatment was assessed by clinical examination as well as by 
imaging techniques if required on follow up. 
Results: High-dose-rate brachytherapy was tolerated by all patients. 
Only 2/24 (0.08%) patients developed bleeding complication. Local 
control was seen in 83.33% of patients among which 9/11 patients 
(81.8%) were in early stage and 11/13 (84.61%) patients were in 
locally advanced stage. (This is an ongoing study.) 
Conclusions: High-dose-rate brachytherapy as a boost for patients 
with primary squamous cell carcinomas of the oral cavity will help 
improve local control. It limits the volume of tissue exposed to high 
doses of radiation therapy. It has showed effective local control in 
early and locally advanced stages. 
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Purpose/Objective: Glomus tumors are rare tumors that are highly 
vascular and typically radiosensitive. Therapeutic options include 
surgery, radiation therapy, embolisation or any combination, but the 
appropriate treatment still remains challenge. The aim of this article 
is to report the results local control of 7 patients with glomus tumors 
treated with surgery and external beam radiotherapy at the Institute 
of Oncology and Radiology of Serbia.  
Materials and Methods: Follow-up was calculated from the date of 
initiation of RT for all patients. Patients had minimum follow-up time 
as 3 years and maximum follow-up as 15 years (mean, 7,14 years, 
median 6,2).The likelihood of local control was analyzed using the 
Kaplan-Meier product limit method. We also analyzed average 
duration of response between two groups of patients with different 
dose of radiation as well as presence of acute and late complications 
of RT.  
Results: Local control was obtained in 85,7% treated patients (6 of 7 
patients). Moreover, local control was achieved in 75% of treated 
patients with recurrent glomus tumors (3 of 4 patients),while in 
patients with residual disease local control was obtained in 100% of 
patients (3 of 3 patients). In our study, patients who received 
radiation therapy with dose less than 50Gy (2patients) had shorter 
average duration of response compared to patients who received 
higher than 50Gy (5 patients). There were no severe treatment 
complications. 
Conclusions: Surgery and radiation therapy are appropriate treatment 
approach for advanced glomus tumors with acceptable complications. 
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Purpose/Objective: The purpose of this retrospective cohort study 
was to identify clinical factors and/or DVH parameters associated with 
acute oral and pharyngeal toxicities (feeding tube, FT rate used as 
surrogate) in head and neck cancer patients treated with definitive 
chemoradiotherapy (CRT). 
Materials and Methods: From 2005-10, 174 patients with unknown 
primary (UKP)(n=18), oropharyngeal (n=122) and nasopharyngeal 
(n=33) squamous cell carcinoma (SCC) were prospectively treated with 
definitive radiotherapy (RT), with or without chemotherapy (CT). 
Median age was 54 years (range, 17-80). One, 13, 31, 107 and 4 
patients presented with stage I, II, III, IVa and IVb disease, 
respectively. Neoadjuvant chemotherapy (CT) was administered in 123 
patients (70%). Cisplatin (Cis) (n=100), carboplatin (Cb) (n=29) or Cis 
followed by Cb (n=20) based CT were given concomitantly with RT. 
Patients were treated with IMRT, delivering 65 Gy in 30 daily fractions 
to PTV1 (macroscopic disease) and 54 Gy in 30 daily fractions to PTV2 
(lymph nodes at risk, or nasopharyngeal mucosa for the UKP cancer 
patients). Reactive as opposed to prophylactic FT insertion policy was 
used. Acute toxicity (NCICTCv.2.0) was recorded prospectively at 
weeks 1–6 during and 1–4 post treatment. Organs at risk potentially 
involved in acute mucosal toxicity and swallowing including the 
superior, middle and inferior pharyngeal constrictor muscles and the 
oral (OM) and pharyngeal mucosae (PM) were delineated on the 
planning CT-scan. Dosimetric and clinical variables including N stage, 
age, gender, type of chemotherapy, smoking status, alcohol 
consumption and RT timing (8-11am vs 11-3pm vs 3-6 pm) were 
entered in a logistic regression analysis. 
Results: Severe acute dysphagia (FT) (Grade 3-4) and severe oral 
mucositis were observed in 85 (49%) and 88 (50%) patients, 
respectively. On univariate analysis, the mean dose to the OM and Cis 
based concomitant CT were significant factors for developing G≥3 oral 
mucositis (p=0.039 and p=0.013, respectively). As expected, patients 
who presented with an UKP SCC developed less G≥3 mucositis 
(p=0,012). These variables remain statistically significant in the 
multivariate analysis. FT rate was also significantly associated with 
the administration of Cis based concomitant CT (50 vs 46%, p=0.045). 
The maximum dose to the OM was also a significant prognostic factor 
for FT. These two variables remain significant in the multivariate 
logistic regression model. A statistical trend was observed, in 
addition, for patients receiving or not cisplatin-5FU induction CT, the 
later presenting less Grade ≥3 acute dysphagia: 55% vs. 41%, 
respectively (p=0.08). None of the other clinical variables mentioned 
above (dose to the constrictors and pharyngealmucosa in particular) 
correlated significantly with FT rates. 
Conclusions: The incidence of acute oral and pharyngeal toxicities 
remain high in head and neck patients treated with CRT. Type of 
chemotherapy and dose distribution to the oral mucosa alone seem to 
be of particular significance. 
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Purpose/Objective: Significant anatomical and volumetric changes 
occur in H&N cancer patients during fractionated radiotherapy (RT). 
The aim of this study was to assess the dosimetric changes and 
investigate its correlation to clinical parameters during a 6 week 
curative course of RT for H&N squamous cancers (HNSCC). 
Materials and Methods: Seventeen patients of HNSCC treated with 
inversed planned image guided IMRT using Tomotherapy Hi-Art was 
selected. The Planning Target volume (PTV) and organs at risk (OARs) 
including bilateral parotids and constrictor muscles were contoured. 
Daily megavoltage CT (MVCT) scans were acquired during treatment as 
per institutional policy; of which ones during fraction 1,15 and 30 was 
used to calculate changes in the dose to the PTV, constrictors and 
parotids. Patient’s weight, mid upper arm circumference (MUAC), mid 
arm muscle circumference (MAMC) and triceps thickness (TS) were 
recorded prior to, midway and at completion of RT (30th fraction). 
Correlation coefficients between the dosimetric and clinical changes 
was calculated to investigate whether it was possible to predict 
dosimetric changes using early clinical variables. 
  
  
  
  
 
  
